Thermo Fisher Scientific Reports 9% Revenue Growth to $12.14 Billion

Thermo Fisher Scientific reported third-quarter revenue of $12.14 billion, up 9% from $11.12 billion a year earlier, with its laboratory products and biopharma services division providing the largest increase in sales. Organic revenue growth was 6%, pointing to expansion within existing operations as well as the effect of changes to the company’s business portfolio.

Earnings grew faster than revenue. Adjusted profit reached $6.68 a share, a 15% increase from $5.79 in the same quarter of 2025, while diluted earnings per share under generally accepted accounting principles rose 9% to $4.64. Both profit measures improved, though they are calculated on different bases and should not be treated as interchangeable.

The results cover the three months ended September 26, 2026. In its October 21 earnings release, the Waltham, Massachusetts-based company reported that acquisitions and divestitures added a net three percentage points to its year-over-year revenue growth calculation. Currency translation contributed no percentage-point change. That reconciles the 9% reported increase with the 6% organic growth figure, which Thermo Fisher defines as a non-GAAP measure.

Biopharma and laboratory businesses drove the sales increase

Laboratory Products and Biopharma Services generated $6.86 billion in quarterly revenue, compared with $5.97 billion a year earlier. The increase of about $893 million, or roughly 15%, was the largest dollar gain among Thermo Fisher’s four reported business segments. The division covers a broad range of laboratory products and pharmaceutical services, making its performance central to the overall revenue result.

Two other segments recorded more modest gains. Life Sciences Solutions revenue increased to $2.72 billion from $2.59 billion, while Analytical Instruments rose to $2.00 billion from $1.89 billion. Those increases show that growth was not confined to the largest segment, although neither matched its pace. Together, the figures also make clear why a consolidated 9% increase does not describe the experience of every operating business.

Specialty Diagnostics moved in the opposite direction, with revenue falling to $1.10 billion from $1.17 billion. Its segment income nonetheless rose to $341 million from $321 million, and its segment margin improved to 31.0% from 27.4%. The earnings release provides those results but does not attribute the change in profitability to a single driver. Sales weakness in the division therefore needs to be considered separately from its reported margin improvement.

The diagnostics comparison also comes after a portfolio change. Thermo Fisher completed the sale of its microbiology business to private-equity firm Astorg on August 12 for approximately $1.075 billion, including a $50 million seller note. The business, which recorded $645 million in 2025 revenue, had been included within Specialty Diagnostics. Thermo Fisher did not specify in the third-quarter release how much of that segment’s year-over-year revenue decline resulted from the sale, so the entire reduction should not be attributed to the divestiture.

For the first nine months of 2026, consolidated revenue reached $35.14 billion, up from $32.34 billion in the comparable period last year. That broader comparison puts the third-quarter increase alongside growth across the year to date without obscuring the different trajectories of the individual divisions.

Operating margins and cash generation strengthened

Thermo Fisher reported $2.26 billion in GAAP operating income for the quarter, versus $1.94 billion a year earlier, an increase of approximately 17%. The operating margin rose to 18.6% from 17.4%. The income statement shows that cost of revenue accounted for 57.2% of sales, compared with 58.2% last year, and selling, general and administrative expenses declined as a share of sales as well. These changes supported the higher reported operating margin without identifying any single operational cause.

On an adjusted basis, operating income was $2.97 billion, up from $2.59 billion, and the margin reached 24.5%, compared with 23.3% a year earlier. The company’s adjusted figures remove specified expenses, including acquisition-related intangible-asset amortization and restructuring costs. Such exclusions can help readers examine a different measure of operating performance, but the GAAP figures remain essential for understanding reported expenses and profit.

The financial statements filed with the SEC show quarterly net income attributable to Thermo Fisher of $1.72 billion, compared with $1.62 billion a year earlier. Weighted-average diluted shares declined to about 371 million from 378 million. That lower share count helps explain why the 9% growth in reported earnings per share exceeded the increase in attributable net income. The filing does not, by itself, establish the causes of the share-count change.

Cash generation also improved. Net cash provided by operating activities increased to $2.55 billion from $2.24 billion, even as capital spending rose to $437 million from $404 million. Thermo Fisher reported third-quarter free cash flow, a non-GAAP measure, of $2.12 billion, compared with $1.84 billion a year earlier. Across the first nine months, its free cash flow totaled $4.62 billion versus $3.32 billion in 2025. These figures offer a cash-based comparison alongside the two reported earnings measures.

Portfolio changes and new products shape the year-end picture

During the quarter, Thermo Fisher introduced equipment and tools aimed at several research markets. The company highlighted the Orbitrap Isora mass spectrometer, designed for isotope-ratio analysis, and the EMPAD G2 electron detector for advanced-materials research. It also introduced an autoimmune screening test in the United States and a higher-throughput sequencing chip for its Ion GeneStudio S5 platform. The release did not disclose how much third-quarter revenue came from these launches, so their longer-term commercial contribution cannot be measured from the reported sales alone.

A partnership with Mayo Clinic was another development cited by management. The companies launched an initiative called Precure, intended to draw on data from more than one million patient samples and Thermo Fisher’s proteomics technologies to investigate patterns of disease progression and detection. Thermo Fisher also opened an AI-automation innovation center in South Korea and a highly automated distribution center in Kentucky. These announcements describe investments and research activity rather than quantified contributors to the latest quarterly increase.

The figures leave two distinct questions for the remainder of 2026: whether demand in the larger laboratory and biopharma businesses continues at its recent pace, and how Thermo Fisher’s smaller divisions perform after the microbiology sale. The company said updated full-year financial guidance would be provided during its October 21 earnings conference call; revised annual revenue and earnings targets were not included in the written quarterly release.